Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Adagene $25 million strategic equity investment from Sanofi
We advised Adagene on the transaction
Medtide HK$411.2 million IPO
We advised Medtide on its IPO and HKEX listing
Mirxes Holding Company HK$1.09 billion IPO
We advised Mirxes on its IPO and HKEX listing
ADC Therapeutics $100 million private placement
We advised ADC Therapeutics on the equity offering
Omada Health $172.6 million IPO
The shares are listed on the Nasdaq Global Select Market
PegBio IPO
We advised PegBio on its IPO and HKEX listing
Hinge Health $503 million IPO
The shares are listed on the New York Stock Exchange
Kenvue $750 million senior notes offering
The investment-grade notes are due 2032
Atara Biotherapeutics registered direct offering
The stock is listed on Nasdaq
CytomX Therapeutics $100 million stock offering
The stock is listed on the Nasdaq Global Select Market